75438-12-9

Basic information

• Product Name: Benzenamine, 2-chloro-N-methyl-6-nitro-
• CAS NO: 75438-12-9
• Molecular Formula: C7H7ClN2O2
• Molecular Weight: 186.598
• Mol File: 75438-12-9.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Benzenamine, 2-chloro-N-methyl-6-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 2-chloro-N-methyl-6-nitro-(75438-12-9)
• EPA Substance Registry System: Benzenamine, 2-chloro-N-methyl-6-nitro-(75438-12-9)

Safety Data

• Hazardous Substances Data: 75438-12-9(Hazardous Substances Data)

Upstream product

• 769-11-9 2-chloro-6-nitroaniline 
• 74-88-4 methyl iodide 
• 2106-49-2 1-chloro-2-fluoro-3-nitrobenzene 
• 74-89-5 methylamine 
• 64-17-5 ethanol 
• 3209-22-1 1,2-Dichloro-3-nitrobenzene 

Downstream Products

• 102074-47-5 6-chloro-N¹-methylbenzene-1,2-diamine 
• 1267635-03-9 C₂₀H₂₀ClN₃O₃ 
• 1267635-68-6 C₁₆H₁₃ClN₂O₂ 
• 4887-87-0 7-chloro-1-methyl-1H-benzo[d]imidazole 
• 24133-88-8 7-chloro-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one 

Relevant articles and documents

Spiroconjugated Tetraaminospirenes as Donors in Color-Tunable Charge-Transfer Emitters with Donor-Acceptor Structure

Charge-transfer emitters are attractive due to their color tunability and potentially high photoluminescence quantum yields (PLQYs). We herein present tetraaminospirenes as donor moieties, which, in combination with a variety of acceptors, furnished 12 charge-transfer emitters with a range of emission colors and PLQYs of up to 99 %. The spatial separation of their frontier molecular orbitals was obtained through careful structural design, and two DA structures were confirmed by X-ray crystallography. A range of photophysical measurements supported by DFT calculations shed light on the optoelectronic properties of this new family of spiro-NN-donor-acceptor dyes.

TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE

This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such bivalent compounds.

Discovery of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly

The discovery of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly is described. Synthesis of analogs of the 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione hit established structure-activity relationships. Replacement of the enamine functionality of the hit series with either an imidazole or a pyrazole ring led to compounds that inhibited both capsid assembly and reverse transcriptase. Optimization of the bicyclic benzodiazepine scaffold to include a 3-phenyl substituent led to lead compound 48, a pure capsid assembly inhibitor with improved antiviral activity.